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Abstract: Angiosarcoma is an extremely rare and aggressive malignancy. Standard of care of localized
tumors includes surgery ± radiation. Despite this multimodal treatment, >50% of the angiosarcoma
patients develop local or distant recurrent disease. The role of neoadjuvant systemic therapy is still
controversial and we therefore performed a systematic review of the literature to define the role of
neoadjuvant systemic therapy based on available evidence. We focused on the effects of neoadjuvant
systemic therapy on: 1. The success of surgical resection and 2. the long-term survival. All articles
published before October 2019 on Ovid Medline, Ovid Embase, Cochrane library and Scopus were
evaluated. Eighteen case reports and six retrospective cohort studies were included. There were no
randomized controlled trials. This literature showed a beneficial role of neoadjuvant chemotherapy
on downsizing of the tumor resulting in an improvement of the resection margins, especially in
patients with cardiac or cutaneous angiosarcoma. However, no definitive conclusions on survival
can be drawn based on the available literature lacking any prospective randomized studies in this
setting. We advise that neoadjuvant chemotherapy should be considered, since this could lead to
less mutilating resections and a higher rate of free resection margins. An international angiosarcoma
registry could help to develop guidelines for this rare disease.
Keywords: sarcomas; angiosarcoma; neoadjuvant treatment; neoadjuvant therapy; outcome
1. Introduction
Angiosarcoma is an aggressive sarcoma subtype, mostly deriving from endothelial cells of vascular
or lymphatic origin. This neoplasm most frequently arises in (sub)cutaneous blood vessels, but can
arise throughout the whole body [1]. Angiosarcoma is extremely rare and accounts for less than 1% of
all soft tissue sarcomas in adults with an incidence of 1.5 per 1,000,000 persons per year [2,3]. Some case
reports suggest that several familial syndromes could possibly predispose for angiosarcoma, such as a
mutation in the BRCA1 or BRCA2 gene [4,5].
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Angiosarcomas can be divided into different subgroups, primary (sporadic) or secondary,
based on the etiology of the disease [6,7]. Primary or sporadic angiosarcoma arise from progenitor or
mesenchymal stem cells anywhere in the body, but seem to have a slight predilection for the breast [7,8],
while secondary angiosarcomas are mostly seen on the skin because they are caused by external damage
by radiation, UV-exposure or chronic lymphedema [7]. The most common variant is the UV-induced
angiosarcoma, usually arising in the skin of the face and scalp (35–62%) of mainly elderly patients [1,2,9].
Radiation associated angiosarcoma can occur anywhere in the body after previous radiation but is most
frequently seen in the breast after previous radiotherapy for a primary breast malignancy. It is estimated
that around 1 in 10,000 patients per year previously treated for a malignancy with radiation, sooner or
later develops angiosarcoma in the inflicted area [1,10]. Angiosarcoma in the extremity can be caused by
chronic lymphedema and this disease is also known as Stewart-Treves syndrome [1,10]. The incidence of
Stewart-Treves syndrome is between 1/10 and 1/20 of patients with cutaneous angiosarcoma [1]. Finally,
several exogenous toxins are associated with the development of angiosarcoma, especially within the
liver [11,12]. The separation in primary and secondary angiosarcoma is important, because there is a
difference in prognosis. Patients with secondary angiosarcoma show a better median overall survival
than patients with primary angiosarcoma, 20.6 vs. 7.2 months, respectively [7].
The standard of care for resectable localized disease is complete surgical resection. Despite this
treatment, more than 50% of patients develop local (26–54%) or distant (>50%) recurrent disease [13,14]
and only 60% of patients who initially present with localized disease survive for more than 5 years [15],
meaning there is an urgent need to improve the treatment. Given this high-risk and poor prognosis
of angiosarcoma, ESMO guidelines state that neoadjuvant radiation and chemotherapy may be
considered [16]. Current practice regarding (neo)adjuvant treatment, however, varies widely
per country and per institution. Then again, conclusive data regarding the response rates and
potential survival benefit of (neo)adjuvant chemotherapy is lacking, and in modern times neoadjuvant
chemotherapy is often preferred over adjuvant chemotherapy to enable response evaluation and
change chemotherapy regimen when no response is observed.
In general, goals of neoadjuvant systemic treatment are: (1) to facilitate adequate surgical
resection by downsizing the tumor and (2) to improve survival by treating distant micrometastases,
preventing outgrowth of these metastases into macrometastases. The addition of neoadjuvant systemic
therapy to angiosarcoma treatment, however, is based on relatively limited available data, and consists
mostly of retrospective studies and case reports. Designing a large randomized study analyzing
neoadjuvant systemic therapy for angiosarcoma would be challenging, given the rarity of the disease
and the different angiosarcoma subtypes with different biological behavior. With this review, we aim
to provide a summary of the current literature on neoadjuvant systemic treatment of angiosarcoma.
Furthermore, we aim to analyze outcome and response rates of neoadjuvant systemic therapy and
evaluate tumor resectability after neoadjuvant systemic therapy. Recommendations based on available
literature are given.
2. Results
The literature search resulted in six retrospective cohort studies and eighteen case reports with
21 individual cases discussing neoadjuvant systemic treatment (Figure 1). Tables 1 and 2 give an
overview of the short-term and long-term outcome and of the effect of neoadjuvant systemic treatment
on surgical margins of angiosarcoma patients in these studies. The retrospective cohort studies
will first be discussed in more detail. The six retrospective cohort studies consist of one study with
angiosarcoma of the face and scalp only, two studies discussing all cutaneous angiosarcoma, two studies
discussing cardiac angiosarcoma and one study discussing all kinds of angiosarcoma. Secondly, the case
reports will be discussed per tumor localization, because the site of origin of the disease affects the
prognosis [14,15].
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Table 1. Overview of responses to neoadjuvant systemic treatment in angiosarcoma patients – retrospective cohort studies.
Refs No. ofPatients Neoadjuvant Treatment Patient Characteristics
Influence on
Resectability Short-Term Response Long-Term Response
[17] 33
10 pts docetaxel + gemcitabine
5 pts paclitaxel
18 pts had diverse regimens
consisting of doxorubicin +
ifosfamide, cyclophosphamide +
doxorubicin + dacarbazine,
interferon, vincristine, doxorubicin +
paclitaxel or other combinations
70 pts with non-metastatic AS of
face and scalp
-33 pts had NAC (regimen per pt.
was ns)
20 pts had AC
9 pts had both
ns
88% response: 11 pts had
CR and
18 pts had PR
2 pts had SD (6%)
2 pts had PD (6%)
Chemotherapy was not associated with
a significant difference in OS or DSS,
local or distant recurrence compared to
pts who did not received chemotherapy
[13] 12
12 pts had ≥2 cycles of NAC:
- Paclitaxel (n = 6)
- Gemcitabine + docetaxel (n = 4)
- not specified for 2 pts
23 pts with primary cutaneous or
soft tissue AS
80% R0 resections
after NAC (vs. 85%
surgery alone)




-2 PD during NAC
(both paclitaxel)
No statistically significant survival
benefit in pts who received NAC when
compared to pts who did not
receive NAC
[18] 38
38 pts had NAC: site of origin AS
and regimens were ns
21 pts had RT
821 localized AS ns No short-term FUdata available
Neither RT nor chemotherapy improved
the OS
[19] 10 10 pts had NAC: regimens were ns
46 pts with primary cardiac
sarcomas who underwent heart
transplantation-(16 pts had AS)
ns No short-term FUdata available
NAC did not provide survival benefit
after heart transplantation compared to
pts who only received heart
transplantation
[20] 24
Median of 6 cycles of doxorubicin +
ifosfamide or gemcitabine +
docetaxel
32 pts with right sided heart
sarcoma had NAC (24 with AS)
47% R0 resections





Median survival 20 months with NAC
vs. 9.5 months without NAC (p = 0.417).
Median survival higher after R0
resection (53.5 vs. 9.5 months positive
margins, p = 0.004)
[14] 17 Doxorubicin +/− ifosfamide
9 pts received NAC
7 pts after R2 resection or for
inoperable disease
ns
3 pts had CR (18%)
7 pts PR (41%)
2 pts SD (12%)
5 pts PD (29%)
No significant differences in OS or PFS
between pts who received NAC
compared to pts without NAC
AC = adjuvant chemotherapy, AS = angiosarcoma, CR = complete response, DFI = disease-free interval, DSS = disease specific survival, FU = follow up, NAC = neoadjuvant chemotherapy,
No = number, ns = not specified, OS = overall survival, pCR = pathologic complete response, PR = partial response, pt.(s) = patient(s), refs = references, vs. =versus RT = radiotherapy.
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Table 2. Overview of responses to neoadjuvant systemic treatment in angiosarcoma patients—case reports.
Case Report
Reference Neoadjuvant Treatment Patient Characteristics Short-Term Response Long-Term Response
Primary angiosarcoma of the breast
[21] 4 cycles of ifosfamide, vincristine anddactinomycin 1 pt. Tumor reduction of 50% Disease free after 2 yrs. of FU
[22] Arterial injection with cyclophosphamideand 5-FU 1 pt. No short-term FU data available Disease free after 15 months of FU
[23] Gemcitabine and docetaxel 1 pt. pCR No evidence of recurrence 20 monthsafter the initial diagnosis
[24] Gemcitabine and docetaxel 1 pt. pCR Disease free after 2 yrs. of FU
[25]
4 cycles of cisplatin, doxorubicin and
thalidomide, followed by paclitaxel,
cisplatin and thalidomide
1 pt. pCR in the breast and axillarylymph nodes
No recurrence 6 months after the
initial diagnosis
Radiation induced angiosarcoma of the breast
[26] 4 cycles of gemcitabine and docetaxel 1 pt.
Clinical improvement after
2 cycles, near CR on MRI after
4 cycles
No FU data available
[27] 3 cycles of gemcitabine and docetaxel 1 pt. Minimal residual disease inresected tissue Disease free after 9 months of FU
[28] 8 cycles of carboplatin and gemcitabine 1 pt. Improvement of local conditionof the breast No recurrence 1 yr. after the surgery
[29] 3-4 cycles of bevacizumab and RT 50 Gy 2 pts with AS of the face pCR Disease free after 8.5 (pt. 1) and26 months (pt. 2) of FU
[30] 5 cycles of paclitaxelThereafter 5× PDT 1 pt. with AS of the scalp
No metastasis, no improvement
of skin lesions
Improvement of all skin lesions
Disease free after 6 months of FU
[31] 1 cycle of cisplatin, docetaxel and 5-FU 1 pt. with radiation inducedAS of the face
Decreased tumor size from
35 × 21 mm to 19 × 13 mm
on MRI
Lung metastasis after surgery.




Doxorubicin, ifosfamide and dacarbazine
3 pts with post-irradiation
AS (AS location
not specified)
PR 1/3 pts No FU data available
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Table 2. Cont.
Case Report
Reference Neoadjuvant Treatment Patient Characteristics Short-Term Response Long-Term Response
[33]
Doxorubicin, dacarbazine, ifosfamide
and mesna followed by RT 2600 cGy for
1 month
1 pt. Not specified Disease free after 33 months of FU
[34] 3 cycles of doxorubicin and dacarbazine 1 pt. Tumor became operable Disease free after 2 yrs. of FU
[35] 3 cycles paclitaxel 1 pt. with AS of the spleen PR after 3 cycles on CT No recurrence 14 months after startof treatment
[36] Vincristine, cyclophosphamide andactinomycin 1 pt. with calvarial AS PD Disease free after 3 yrs. of FU
[37]
2 cycles of ifosfamide, doxorubicin,
mitomycin, cisplatin and mesna
Followed by 50 Gy and 2 cycles
mitomycin, doxorubicin and cisplatin
1 pt. with AS of seminal
vesicle
After 2 cycles of NAC decreased
tumor size from 5.6 × 5.1 to
4.3 × 4.0 cm
No significant changes after RT
Disease free after 6 yrs. of FU
[38] 1 cycle of taxol, followed by 3 cyclesof gemcitabine
1 pt. with epithelioid AS of
the thyroid
<10% viable tumor cells left in
surgical specimen Disease free after 70 months of FU
AS = angiosarcoma, AT = adjuvant treatment, CR = complete response, CT = computed tomography, FU = follow-up, (c)Gy = (centi)gray, HIPEC = heated (hyperthermic) intraperitoneal
chemotherapy, MRI = magnetic resonance imaging, NAC = neoadjuvant chemotherapy, pCR = pathologic complete response, PD = progressive disease, PDT = photodynamic therapy,
PR = partial response, pt.(s) = patient(s), RFA = radio frequent ablation, RT = radiotherapy, yr.(s), year(s).
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In summary, based on this limited sample size with an unknown patient selection for 
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2.1.1. UV-Induced Angiosarcoma of the Face and Scalp
One of the cohort studies focused on patients with UV-induced angiosarcoma of the face and scalp.
In the cohort published by Guadagnolo et al., 70 patients with angiosarcoma of the face and scalp
were included of whom 44 patients (63%) received chemotherapy (33 neoadjuvant and 11 adjuvant).
The addition of chemotherapy to the standard treatment was independent of the size of the tumor
and most patients received the combination of gemcitabine and docetaxel or paclitaxel single agent.
From the 33 patients with neoadjuvant chemotherapy, eleven patients showed a clinical CR (33%),
eighteen patients a PR (55%), two patients a SD (6%) and two patients PD (6%). Nine of the patients
treated with neoadjuvant chemotherapy also received adjuvant chemotherapy (27%) [17]. In this
study neither the status of the resection margins, nor the addition of chemotherapy had an influence
on the OS or DSS when compared to the patients who did not receive chemotherapy. Neoadjuvant
chemotherapy slightly improved the 5-year distant metastases free survival (38% (n = 33) vs. 69%
(n = 37), p = 0.06), but did not improve the local control after surgery [17].
In summary, based on this limited sample size with an unknown patient selection for neoadjuvant
chemotherapy, no conclusions can be drawn on the effect of neoadjuvant chemotherapy on the local
and distant control rate of UV-induced angiosarcoma of the face and scalp. However, response rates
were relatively high with only 6% PD during chemotherapy.
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2.1.2. Cutaneous Angiosarcoma
While the current European guideline [16] does not provide strict guidance for the use of
neoadjuvant chemotherapy, it was already implemented as standard of care for cutaneous angiosarcoma
in the Roswell Park Center since 2008 [13]. Neoadjuvant chemotherapy is used to treat occult
micrometastases and to identify patients who would not benefit from a potentially morbid surgery.
Patients who develop metastases or with rapid PD during neoadjuvant chemotherapy, would be
excluded from extensive surgery. Oxenberg et al. retrospectively compared data from patients
with neoadjuvant chemotherapy and surgery with surgery alone [13]. They included 25 patients
treated between 1996–2012 with cutaneous angiosarcoma at different locations, including breast and
head and neck. From these patients, thirteen patients had a primary resection and twelve patients
were treated more recently and started with neoadjuvant chemotherapy of whom eventually ten
patients underwent surgery. Two patients, who developed distant metastases during neoadjuvant
chemotherapy, were excluded from further comparisons. The response and outcome analyses were
performed for the two subgroups as total (surgery alone (n = 13) vs. neoadjuvant chemotherapy and
surgery (n = 10)), despite the heterogeneity of tumor localizations and the difference in follow-up
time within the groups. Two different chemotherapeutic regimens were given: paclitaxel (n = 6)
or gemcitabine plus docetaxel (n = 4). There were no differences in resection margins or type of
wound closure between the two groups. Thirty percent of the neoadjuvant chemotherapy cohort
had a pathologic CR (pCR), however, neoadjuvant chemotherapy did not improve the local RFS,
distant DSS, DSS or OS [13]. On the other hand, delay in surgery due to neoadjuvant chemotherapy
did not negatively influence the outcome of these patients either.
Sinnamon et al. searched a large national database and included 821 patients with localized
cutaneous and soft tissue angiosarcoma, who underwent surgery [18]. They excluded patients who
died within 90 days after surgery, which could have confounded the results. Of the 821 patients,
26% was located in the head and neck region. Overall, only 38 patients (5%) received neoadjuvant
chemotherapy, but the rationale for choosing neoadjuvant treatment in these patients was not specified.
Nevertheless, both neoadjuvant (median OS 3.1 years, n = 38) and adjuvant chemotherapy (median OS
3.8 years, n = 128) did not improve the median OS compared to the median OS of patients without
chemotherapy (3.4 years, n = 655) [18]. Of note, the results could be biased, because patients with a
worse prognosis, caused by larger tumors or tumors which are located in areas which are difficult to
operate, are more likely to receive neoadjuvant treatment. Furthermore, no information about the
chosen regimen was provided, which makes it complicated to interpret these results, because the
type of chemotherapy could also affect the outcome of patients. The large number of patients in this
cohort created the opportunity to identify factors associated with poor OS using Cox proportional
hazards modeling. Factors significantly associated with poor survival, with descending hazard ratio
(HR), were tumor size > 7 cm (HR 2.37), age > 70 years (HR 2.02), Afro-American race (HR 1.92),
tumor size 3–7 cm (HR 1.64), positive resection margins (microscopic HR 1.59, macroscopic HR 3.38),
grade 3 tumor (HR 1.52) and head and neck as primary localization (HR 1.44) [18].
To conclude, both cohort studies investigated the effect of neoadjuvant chemotherapy in patients
with non-metastatic cutaneous or soft tissue angiosarcoma and found no survival benefit, but also no
dismal effects of delaying the resection.
2.1.3. Cardiac Angiosarcomas
Two of the retrospective cohort studies investigated cardiac sarcomas. Li et al. focused on the
survival after a heart transplantation as an uncommon treatment of unresectable non-metastatic cardiac
sarcomas in six cases from their own institute and 40 patients from the literature [19]. Among the
46 patients receiving heart transplantation for primary cardiac sarcoma, angiosarcoma was the
most common histologic subtype (n = 14, 30%). The 46 patients with a heart transplantation were
compared to seven patients with unresectable, non-metastatic cardiac sarcomas of the same institute
who only received palliative treatment (systemic therapy or radiotherapy), due to patient choice or
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unavailability of a donor heart [19]. They found that the survival after heart transplantation was
worse for angiosarcomas than other cardiac sarcomas (9 vs. 36 months, p = 0.002) and the survival
after heart transplantation was comparable to patients receiving palliative systemic treatment only
(9 vs. 8 months, p = 0.912) [19]. Furthermore, neoadjuvant as well as adjuvant chemotherapy did not
improve the survival for all cardiac sarcoma patients (15 vs. 18 months, p = 0.210, and 15 vs. 26 months,
p = 0.088, respectively) [19]. However, the rationale for the addition of neoadjuvant chemotherapy was
not given in the manuscript.
Abu Saleh et al. have previously shown that in the treatment of cardiac sarcomas R0 resection
margins resulted in better OS, but this was not easily achieved [20]. They hypothesize that neoadjuvant
chemotherapy could result in debulking of the tumor and therefore could aid in achieving negative
margins during surgery. They included 44 cardiac sarcoma patients of whom the majority had
angiosarcoma (n = 30, 68%). As part of a clinical trial to investigate the effect of neoadjuvant
chemotherapy on the survival, 32 patients received neoadjuvant chemotherapy, of which 24 (80%)
patients with angiosarcoma. The demographic characteristics were comparable between the group
who received neoadjuvant chemotherapy and the group who received no chemotherapy. However,
stage at start of treatment differed between the groups, 63% of the patients in the neoadjuvant
group had distant metastases and only 33% in the group treated without chemotherapy (p = 0.082).
The first line neoadjuvant treatment of the sarcoma patients consisted of doxorubicin plus ifosfamide
and the second line consisted of gemcitabine plus docetaxel. Both patients with local and limited
metastasized disease were included, if they were considered eligible for surgery. An R0 resection
resulted in a five times longer median survival and neoadjuvant chemotherapy doubled the R0 resection
rate (24% vs. 61%, p = 0.03) [20]. The 30-day mortality rate was lower in the group who received
neoadjuvant chemotherapy but not significantly (3 vs. 8%, p = 0.476) and there was no difference in
30-day postoperative complications [20].
Based on these two retrospective cohort studies, the addition of neoadjuvant chemotherapy to
resection of the tumor could be a preferable therapeutic approach with a good safety profile and an
improved R0 resection rate in a selective patient group of operable cardiac angiosarcoma. In inoperable
non-metastatic cardiac sarcoma patients, a heart transplantation with or without neoadjuvant or
adjuvant chemotherapy does not result in a survival benefit.
2.1.4. Other
The group of Fayette et al. looked into a dataset of 164 patients with all the different histological
angiosarcoma subtypes [14]. From these patients, data regarding systemic treatment was available of
144 patients. Seventeen patients received chemotherapy after R2 resection or for inoperable disease,
with a 59% response rate (18% CR, 41% PR), 12% SD and 29% PD during treatment. The demographic
characteristics of the different treatment groups were not compared in this study. Treatment regimens
were either doxorubicin alone, ifosfamide alone or a combination of doxorubicin with ifosfamide.
However, chemotherapy did not result in a significant difference in OS or PFS [14]. Smaller tumor size
(<5 cm), histological grade (low and no necrosis) and R0 resections were associated with a better OS [14].
Neither the rationale for the addition of neoadjuvant chemotherapy to standard treatment, nor the
precise response rate of the patients who received neoadjuvant chemotherapy was provided [14].
Furthermore, another chemotherapy regimen could have resulted in more activity as most current
studies use a taxane based regimen.
2.1.5. Conclusions Retrospective Cohort Studies
The cohort studies consisted of very heterogeneous patient groups, treated with various regimens.
Patient selection for neoadjuvant chemotherapy was often not substantiated, allowing potential
selection bias. Therefore, no definite conclusions regarding outcome benefit for these patients can be
drawn based upon this data.
Cancers 2020, 12, 2251 9 of 15
However, within these cohort studies, with heterogeneous treatment regimens and follow-up
periods, the response rate (PR or CR) to neoadjuvant chemotherapy was extremely high with 88% for
face and scalp angiosarcoma [13,14,17–20].
2.2. Case Reports
In total, eighteen case reports describing 21 patients were previously published in the literature.
In this review, we will discuss the cases per tumor localization (Table 2). Potential publication bias
should be considered.
2.2.1. Angiosarcoma of the Breast
Eight cases of angiosarcoma of the breast have been reported of which three especially describe
radiation induced angiosarcoma [23–28]. The patients were treated with a variety of chemotherapy
schedules and all patients showed a response (CR or PR) to neoadjuvant chemotherapy.
From the five patients with primary angiosarcoma of the breast [18–20,26,27], one patient had a
PR (50% tumor reduction after ifosfamide/vincristine/dactinomycin) [21] and three patients had a pCR:
two after treatment with gemcitabine and docetaxel and one after cisplatin/doxorubicin/paclitaxel
given concurrently with thalidomide [18,19,27]. No short term follow-up data on tumor reduction
was available for the fifth case, but the patient was disease free 15 months after neoadjuvant therapy
with an injection of cyclophosphamide/5-FU into the artery that supplied the tumor and surgery [22].
None of the patients had recurrent disease during the reported follow-up period (range 0.5–2 years).
Of the patients with radiation induced angiosarcoma [26–28], all patients were treated with
neoadjuvant gemcitabine, two combined with docetaxel [27,28] and one combined with carboplatin [26].
Each patient showed clinical improvement after chemotherapy and the two patients with available
follow-up data were disease free after 9 months and 1 year, respectively [27,28].
In these cases, angiosarcoma of the breast was quite sensitive to chemotherapy with clinical
responses in all patients. All patients were disease free after a follow-up of 6–24 months. Of note,
non-responding patients are generally not overrepresented in case reports.
2.2.2. Angiosarcoma of the Face and Scalp
Three case reports (four patients) elaborate on neoadjuvant systemic therapy in UV-induced
cutaneous angiosarcoma of the face and scalp [29–31]. Two patients had a pCR after treatment with
bevacizumab and radiotherapy. After 8 and 26 months of follow-up the patients were still disease
free [29]. One patient did not show a response after five cycles of paclitaxel but had a remarkable
response on photodynamic therapy and was still recurrence free after 6 months [30]. The third case
report describes a patient who had a decline of the tumor size after treatment with cisplatin plus
docetaxel plus 5-FU, but unfortunately developed distant metastases shortly after the surgery [31].
In summary, three out of four patients with UV-induced angiosarcoma of the face and scalp had a
response to neoadjuvant chemotherapy. Three patients were disease free after 6–26 months, one had
metastatic disease shortly after surgery. Finally, the study from des Guetz et al. [32] describes three
patients with radiotherapy associated angiosarcoma who were treated with neoadjuvant chemotherapy.
One of these patients had a PR after neoadjuvant chemotherapy. Which chemotherapy regimen this
patient received, was not specified.
2.2.3. Cardiac Angiosarcoma
Two case reports describe patients with cardiac angiosarcoma [33,34]. All patients received
doxorubicin based regimens to enhance the resectability of the tumors followed by resection of
the tumor in one patient [34] and a heart transplantation in another patient [33]. In one patient
neoadjuvant treatment was used to downstage the disease to enable surgery [34]. All patients showed
a positive response to neoadjuvant chemotherapy and are disease free after a follow-up period of
24–33 months [33].
Cancers 2020, 12, 2251 10 of 15
2.2.4. Angiosarcoma with other Origin
The remaining case reports describe four cases with a histologically proven angiosarcoma with
rare sites of origin:, one in the spleen [35], one in the calvarial space [36], one in the seminal vesicle [37],
and one in the thyroid [38]. These four patients received a variety of neoadjuvant therapies, which makes
it difficult to interpret the impact of these separate cases for a general treatment advise. Almost all
patients showed a response to chemotherapy and all patients showed long term disease control after
surgery [35–38].
3. Discussion
Given the often dismal prognosis of angiosarcoma, neoadjuvant systemic therapy is increasingly
being considered as a valid treatment option to downsize the tumor, facilitating adequate surgical
resection, but also to evaluate tumor biology to prevent unnecessary extensive surgery in case of early
metastases, and prolong survival. However, literature discussing neoadjuvant strategies is limited,
as we show in this systematic review. The cohort studies (Table 1) consisted of heterogeneous patient
groups with low patient numbers and included both -prognostically different- primary and secondary
angiosarcomas [7], patients treated with various treatment regimens and with different follow-up
periods. Neoadjuvant chemotherapy was more often added to the standard treatment of recently
diagnosed patients. Patient selection for neoadjuvant chemotherapy was often not substantiated and
therefore, there will almost certainly have been a selection bias. And lastly, with the improvement of
current histological diagnostics, some of the more previously diagnosed angiosarcomas are probably
not real angiosarcomas, but other vascular tumors [7]. The study of Weidema et al. even showed
that 16% of the angiosarcoma patients was wrongly classified as angiosarcoma after reevaluation
of the histological material, however with a clear improvement since the introduction of molecular
diagnostics [7]. Therefore, no definite conclusions can be drawn based on these data. Nevertheless,
within this retrospective cohort studies with heterogeneous treatment regimens, the response rate
(PR or CR) after neoadjuvant chemotherapy was very high for face and scalp angiosarcoma. No survival
benefits were seen after neoadjuvant chemotherapy, although, in fact, this can only be assessed properly
in randomized trials, which are lacking.
Because of the retrospective nature of the studies, these results should be interpreted with caution.
Patient numbers are low and a wide diversity of chemotherapeutic regimens were investigated
within different tumor sites of origin. Besides, patients with locally, primary and recurrent disease
were all included, despite the influence of these characteristics on the outcome of angiosarcoma
patients. Theoretically, patients with recurrent disease, with lymph node dissections or with inoperable
disease might benefit more from neoadjuvant chemotherapy than patients with primary angiosarcoma.
Most importantly, there is an enormous selection bias in patients receiving neoadjuvant chemotherapy,
since neoadjuvant chemotherapy is not standard of care in most hospitals. Patients with more advanced
disease and high-risk disease are probably selected for neoadjuvant chemotherapy, which impacts the
interpretation of survival comparisons with smaller, primary resectable, tumors. Selection bias could
also have occurred the other way around, since mostly younger and more fit patients are selected
for neoadjuvant chemotherapy, because they can manage the treatment toxicity better, which would
result in an overestimation of overall survival. Unfortunately, in most studies, the rationale for patient
selection was not discussed and it is therefore extremely difficult to draw any conclusions on the effect
of chemotherapy on survival.
Additionally, the type of angiosarcoma influences the outcome. For instance, patients with
cardiac or visceral angiosarcoma have a worse prognosis compared to patients with cutaneous
angiosarcoma [7,19,20,27]. Patients with cutaneous UV-induced angiosarcoma have a relatively better
survival, despite the challenge in getting clear surgical margins [18]. Furthermore, these patients
often have multi-satellite disease [17]. In patients with angiosarcoma of the scalp, the aim of
neoadjuvant chemotherapy could primarily be to achieve less (mutilating) surgeries rather than
achieving prolonged survival. Prognostic factors which were independently correlated with a worse
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prognosis were positive resection margins, primary location on the face or scalp, tumor size (>5.0 cm),
grade 3 histology, multi-satellite disease, older age (>70 years), primary angiosarcoma, Afro-American
ethnicity, metastatic disease and worse performance status [7,13–15,18,20]. All these prognostic factors
should be taken into account to make a clean interpretation of the effect of the addition of neoadjuvant
treatment to the standard of care.
Another important conclusion, also highlighted by Oxenberg et al., is that any delay in surgery
caused by neoadjuvant chemotherapy did not seem to influence the outcome, since there was no
difference in outcome between patients who received neoadjuvant chemotherapy and patients who did
not, despite the fact that two patients were progressive under chemotherapy and did not receive the
planned surgery [13]. Additionally, neoadjuvant chemotherapy could offer additional time to observe
the tumor biology and identify these progressive patients who would not benefit from aggressive
surgery [13]. Furthermore, we did not find any studies reporting a worse outcome with the addition of
neoadjuvant chemotherapy. Therefore, the addition of a neoadjuvant treatment to standard of care
could be a safe and individualized option for a selected group of patients [13,20].
Lastly, it is unclear which chemotherapy regimen is giving the best results in angiosarcoma in
general. Despite excellent short-term responses, the benefit for the long-term outcome is debatable.
Taxanes, doxorubicin and gemcitabine regimens all report responses, but alternatives may be considered.
For example, because of the high expression of beta-receptors on vascular tumors the addition
of the β-blocker propranolol to chemotherapy-based regimens might be beneficial according to
literature [39–41]. Furthermore, newer drugs such as checkpoint inhibitors, have shown relatively
good responses in especially the UV-induced angiosarcoma, making this a potential drug to use in the
neoadjuvant and metastatic setting [1,41–44]. In particular in elderly with cutaneous angiosarcoma
paclitaxel may give durable responses [45]. Currently there is one recruiting study in which paclitaxel
is combined with chemoradiation as induction treatment of cutaneous angiosarcoma (NCT03921008).
To summarize, there are several limitations of this review which are important for the interpretation
of the results. Current literature only consisted of retrospective studies of heterogeneous patient
populations with low patient numbers, treated with various regimens and lacking the rationale for
treatment choice or evaluation of possible confounders in treatment response. Considering these
limitations and the challenges in performing a randomized controlled trial in a rare tumor type,
an international registry with data on angiosarcoma could be a very valuable source of information.
An easily accessible registry could help to develop international treatment guidelines, identify new
treatment targets and elucidate angiosarcoma characteristics. Recently in the US, a project was set up
to collect angiosarcoma patient data. Patients are approached via social media and patient advocacy
groups and give their consent online, making it a very innovative patient-partnered approach [46].
Expansion of this kind of databases to other countries, would help in the design and execution of
new randomized trials, to increase patient numbers, and provide internationally accepted treatment
guidelines. But the challenge of data protection is certainly something that needs to be addressed.
4. Materials and Methods
A search was performed in Ovid Medline, Ovid Embase, Cochrane library and Scopus with
thesaurus terms and words in title, abstract and (author) keywords. We searched for angiosarcoma,
hemangiosarcoma and lymphangiosarcoma in combination with terms for ‘neoadjuvant therapy’,
‘preoperative therapy’, ‘targeted therapy’ and ‘immunotherapy’. The searches were performed on
25 October 2019. We applied no limits in publication date. Additional articles were included using
citation snowballing. Selection of relevant studies was performed independently by two authors.
Conflicts in the selection of relevant articles were resolved by discussion. All studies that evaluated the
effect of neoadjuvant systemic therapy in the treatment of primary, secondary or recurrent angiosarcoma
on the resection margins and the long-term survival were eligible. A quality assessment was performed
using the Newcastle Ottawa scale for cohort studies (Table S1) [47].
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In this systematic review the terms complete response (CR), partial response (PR) and progressive
disease (PD) refer to the terms as defined in the Response Evaluation Criteria in Solid Tumors
(RECIST) [48] and were mostly measured clinically. Outcome was given in terms of disease- free
interval (DFI), progression free survival (PFS), disease specific survival (DSS) and overall survival (OS).
5. Conclusions
Unfortunately, no definitive conclusions can be drawn regarding the outcome benefit of
neoadjuvant chemotherapy in patients with angiosarcoma based on the current literature. All available
studies were retrospective with heterogeneous, small patient groups and diverse treatment regimens
with the inherent limitations. Keeping these limitations in mind, however, the retrospective cohort
studies and case reports suggest that angiosarcoma is relatively sensitive to chemotherapy (response rate
of 88–93% in patients with angiosarcoma of face and scalp). Neoadjuvant chemotherapy could therefore
probably be used to downsize the tumor. This downsizing could result in more resections with
curative intend, less mutilating resections and a higher R0 resection rate (an increase of 5–14% of all
angiosarcomas to even 50% of cardiac angiosarcomas). The studies show no clear survival benefit.
Nevertheless, there is an urgent need for more studies addressing the role of neoadjuvant systemic
therapy in angiosarcoma and an international angiosarcoma registry could help to develop guidelines.
Recommendations Based on This Review of the Literature
• Neoadjuvant chemotherapy could be considered to downsize the tumor, since this could lead to
less mutilating resections and a higher R0 resection rate.
• There is no survival benefit, but also no evidence of detriment of neoadjuvant chemotherapy.
• There is currently no evidence of the best possible chemotherapy regimen and apart from age of the
patient, also the subtype may help define the treatment choice. In particularly for UV-exposed scalp
angiosarcoma in elderly, paclitaxel is generally well tolerated and more recently also checkpoint
inhibitors are showing interesting responses.
• An international angiosarcoma registry should be set up to collect all available data on
angiosarcoma patients and help to develop guidelines.
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